肝癌免疫检查点抑制剂治疗相关不良反应及处理

王汉萍

doi:10.3969/j.issn.1001-5256.2022.05.003

肝癌免疫检查点抑制剂治疗相关不良反应及处理

DOI: 10.3969/j.issn.1001-5256.2022.05.003

王汉萍^, ,

北京协和医院呼吸与危重症医学科，北京 100005

利益冲突声明：作者声明不存在利益冲突。

详细信息

通信作者:
王汉萍，wanghp@pumch.cn

计量
- 文章访问数: 992
- HTML全文浏览量: 325
- PDF下载量: 225
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-09
- 录用日期: 2022-04-11
- 出版日期: 2022-05-20

Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures

Hanping WANG^{,
,}

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing 100005, China

More Information

Corresponding author: WANG Hanping, wanghp@pumch.cn(ORCID: 0000-0003-3540-2280)

摘要

摘要: 免疫检查点抑制剂(ICI)通过增强机体自身的抗肿瘤免疫来治疗肝癌，已经成为肝癌领域的重要治疗手段。但是，ICI激活抗肿瘤的同时，也会带来一系列特殊的毒副作用，即免疫相关不良反应(irAE)。随着ICI的广泛使用，irAE已经成为临床实践种的一项重大挑战。irAE潜在的疾病谱广泛，包括70多种不同的病理状态，其中程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抑制剂相关的irAE最常见的类型为皮肤毒性、内分泌系统毒性、肺炎以及消化道毒性等，罕见的irAE包括中枢神经系统和心血管、肾脏、血液系统等。irAE疾病谱的广泛性要求对其进行多学科的协作管理，目前国内外也已经有多个学术机构或平台制定了多个irAE管理相关的指南。然而，irAE的管理目前尚缺乏高级别前瞻性试验结果的支持，在临床上也体现出不同于各系统原有免疫病的特点，尚需进一步优化其管理。本文对于肝癌免疫治疗中出现irAE的流行病学、风险及预测因素、各系统irAE的临床特点、治疗及管理注意事项等各个方面进行详细阐述。
- 肝肿瘤 /
- 免疫抑制剂 /
- 药物相关性副作用和不良反应
Abstract: Immune checkpoint inhibitors (ICIs) exert a therapeutic effect on liver cancer by enhancing the body's anti-tumor immunity and have become an important treatment method in the field of liver cancer. However, while ICIs activate the anti-tumor immunity, they also bring a series of special toxic and side effects, i.e., immune-related adverse events (irAEs). With the wide application of ICIs, irAEs have become a major challenge in clinical practice. Such irAEs have a wide potential disease spectrum and include more than 70 different pathological states, and the most common types of irAEs associated with PD-1/PD-L1 inhibitors are skin toxicity, endocrine toxicity, pneumonia, and digestive tract toxicity, while rare irAEs include the toxicity of the central nervous system and the cardiovascular, renal, and blood systems. The wide disease spectrum of irAEs requires multidisciplinary collaborative management, and at present, many academic institutions or platforms in China and globally have formulated various guidelines for irAE management. However, the management of irAEs currently lacks the support of the results of high-level prospective trials, and the characteristics of irAEs are different from the original immune diseases of various systems; therefore, its management needs to be further optimized. This article elaborates on the epidemiology of irAEs in immunotherapy for liver cancer, related risk and predictive factors, clinical features of irAEs involving different systems, and precautions for treatment and management.
- Liver Neoplasms /
- Immunosuppressive Agents /
- Drug-Related Side Effects and Adverse Reactions

HTML全文

参考文献(48)

[1]	HOOS A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations[J]. Nat Rev Drug Discov, 2016, 15(4): 235-247. DOI: 10.1038/nrd.2015.35.
[2]	POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.
[3]	PAUKEN KE, DOUGAN M, ROSE NR, et al. Adverse events following cancer immunotherapy: Obstacles and opportunities[J]. Trends Immunol, 2019, 40(6): 511-523. DOI: 10.1016/j.it.2019.04.002.
[4]	RAMOS-CASALS M, BRAHMER JR, CALLAHAN MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38. DOI: 10.1038/s41572-020-0160-6.
[5]	XU C, CHEN YP, DU XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis[J]. BMJ, 2018, 363: k4226. DOI: 10.1136/bmj.k4226.
[6]	YOEST JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review[J]. Immunotargets Ther, 2017, 6: 73-82. DOI: 10.2147/ITT.S126227.
[7]	PARAKH S, CEBON J, KLEIN O. Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy[J]. Oncologist, 2018, 23(7): 849-851. DOI: 10.1634/theoncologist.2017-0531.
[8]	SANDIGURSKY S, MOR A. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Curr Rheumatol Rep, 2018, 20(10): 65. DOI: 10.1007/s11926-018-0770-0.
[9]	KHOJA L, DAY D, WEI-WU CHEN T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review[J]. Ann Oncol, 2017, 28(10): 2377-2385. DOI: 10.1093/annonc/mdx286.
[10]	LANGER CJ, GADGEEL SM, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508. DOI: 10.1016/S1470-2045(16)30498-3.
[11]	SCHMID P, ADAMS S, RUGO HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. DOI: 10.1056/NEJMoa1809615.
[12]	WOLCHOK JD, CHIARION-SILENI V, GONZALEZ R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(14): 1345-1356. DOI: 10.1056/NEJMoa1709684.
[13]	ABDEL-WAHAB N, SHAH M, LOPEZ-OLIVO MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review[J]. Ann Intern Med, 2018, 168(2): 121-130. DOI: 10.7326/M17-2073.
[14]	KOSTINE M, FINCKH A, BINGHAM CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors[J]. Ann Rheum Dis, 2021, 80(1): 36-48. DOI: 10.1136/annrheumdis-2020-217139.
[15]	LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2): e001072. DOI: 10.1136/jitc-2020-001072.
[16]	Editor-in-chief of the Guidelines Working Committee of the Chinese Society of Clinical Oncology. Guidelines for the management of toxicity related to immune checkpoint inhibitors[M]. Beijing: People's Health Publishing House, 2021: 53. 中国临床肿瘤学会指南工作委员会主编. 免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2021: 53.
[17]	SHI GM, HUANG XY, RENG ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition) [J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594. 施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
[18]	SIBAUD V. Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3): 345-361. DOI: 10.1007/s40257-017-0336-3.
[19]	SOSA A, LOPEZ CADENA E, SIMON OLIVE C, et al. Clinical assessment of immune-related adverse events[J]. Ther Adv Med Oncol, 2018, 10: 1758835918764628. DOI: 10.1177/1758835918764628.
[20]	PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z.
[21]	THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3): 255-289. DOI: 10.6004/jnccn.2019.0013.
[22]	BRAHMER JR, LACCHETTI C, SCHNEIDER BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. DOI: 10.1200/JCO.2017.77.6385.
[23]	BARROSO-SOUSA R, BARRY WT, GARRIDO-CASTRO AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.
[24]	DELIVANIS DA, GUSTAFSON MP, BORNSCHLEGL S, et al. Pembrolizumab-Induced Thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms[J]. J Clin Endocrinol Metab, 2017, 102(8): 2770-2780. DOI: 10.1210/jc.2017-00448.
[25]	LU J, LI L, LAN Y, et al. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis[J]. Cancer Med, 2019, 8(18): 7503-7515. DOI: 10.1002/cam4.2661.
[26]	GEUKES FOPPEN MH, ROZEMAN EA, van WILPE S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management[J]. ESMO Open, 2018, 3(1): e000278. DOI: 10.1136/esmoopen-2017-000278.
[27]	ABU-SBEIH H, ALI FS, LUO W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis[J]. J Immunother Cancer, 2018, 6(1): 95. DOI: 10.1186/s40425-018-0411-1.
[28]	VERSCHUREN EC, van den EERTWEGH AJ, WONDERS J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis[J]. Clin Gastroenterol Hepatol, 2016, 14(6): 836-842. DOI: 10.1016/j.cgh.2015.12.028.
[29]	KLEINER DE, BERMAN D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma[J]. Dig Dis Sci, 2012, 57(8): 2233-2240. DOI: 10.1007/s10620-012-2140-5.
[30]	VITALE G, LAMBERTI G, COMITO F, et al. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: From clinical pivotal studies to real-life experience[J]. Expert Opin Biol Ther, 2020, 20(9): 1047-1059. DOI: 10.1080/14712598.2020.1762562.
[31]	NAIDOO J, WANG X, WOO KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717. DOI: 10.1200/JCO.2016.68.2005.
[32]	WANG H, ZHAO Y, ZHANG X, et al. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study[J]. Cancer Med, 2021, 10(1): 188-198. DOI: 10.1002/cam4.3600.
[33]	MAHMOOD SS, FRADLEY MG, COHEN JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764. DOI: 10.1016/j.jacc.2018.02.037.
[34]	DELANOY N, MICHOT JM, COMONT T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study[J]. Lancet Haematol, 2019, 6(1): e48-e48, e57. DOI: 10.1016/S2352-3026(18)30175-3.
[35]	PERRINJAQUET C, DESBAILLETS N, HOTTINGER AF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy[J]. Curr Opin Neurol, 2019, 32(3): 500-510. DOI: 10.1097/WCO.0000000000000686.
[36]	CUZZUBBO S, JAVERI F, TISSIER M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature[J]. Eur J Cancer, 2017, 73: 1-8. DOI: 10.1016/j.ejca.2016.12.001.
[37]	WANCHOO R, KARAM S, UPPAL NN, et al. Adverse renal effects of immune checkpoint inhibitors: A narrative review[J]. Am J Nephrol, 2017, 45(2): 160-169. DOI: 10.1159/000455014.
[38]	RICHTER MD, CROWSON C, KOTTSCHADE LA, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients[J]. Arthritis Rheumatol, 2019, 71(3): 468-475. DOI: 10.1002/art.40745.
[39]	TOUAT M, MAISONOBE T, KNAUSS S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer[J]. Neurology, 2018, 91(10): e985-e994. DOI: 10.1212/WNL.0000000000006124.
[40]	ESFAHANI K, ELKRIEF A, CALABRESE C, et al. Moving towards personalized treatments of immune-related adverse events[J]. Nat Rev Clin Oncol, 2020, 17(8): 504-515. DOI: 10.1038/s41571-020-0352-8.
[41]	SCHWAB I, NIMMERJAHN F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system?[J]. Nat Rev Immunol, 2013, 13(3): 176-189. DOI: 10.1038/nri3401.
[42]	TOUAT M, TALMASOV D, RICARD D, et al. Neurological toxicities associated with immune-checkpoint inhibitors[J]. Curr Opin Neurol, 2017, 30(6): 659-668. DOI: 10.1097/WCO.0000000000000503.
[43]	BADDLEY JW, CANTINI F, GOLETTI D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents) [J]. Clin Microbiol Infect, 2018, 24(Suppl 2): S10-S20. DOI: 10.1016/j.cmi.2017.12.025.
[44]	BERGQVIST V, HERTERVIG E, GEDEON P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis[J]. Cancer Immunol Immunother, 2017, 66(5): 581-592. DOI: 10.1007/s00262-017-1962-6.
[45]	STROUD CR, HEGDE A, CHERRY C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade[J]. J Oncol Pharm Pract, 2019, 25(3): 551-557. DOI: 10.1177/1078155217745144.
[46]	FRANKLIN C, ROOMS I, FIEDLER M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis[J]. Eur J Cancer, 2017, 86: 248-256. DOI: 10.1016/j.ejca.2017.09.019.
[47]	KUO JR, DAVIS AD, RODRIGUEZ EA, et al. Severe diarrhea in the setting of immune checkpoint inhibitors[J]. Case Rep Gastroenterol, 2018, 12(3): 704-708. DOI: 10.1159/000493183.
[48]	PICCHI H, MATEUS C, CHOUAID C, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment[J]. Clin Microbiol Infect, 2018, 24(3): 216-218. DOI: 10.1016/j.cmi.2017.12.003.